Open AccessOncologist and Patient Preferences for Novel Agents in First-Line Treatment for Chronic Lymphocytic Leukemia: Commonalities and Disconnects
Author(s) -
Hannah Le,
Kellie Ryan,
Svea K. Wahlstrom,
Martine C. Maculaitis,
Oliver Will,
Emily Mulvihill,
Thomas W. LeBlanc
Publication year - 2021
Publication title -
patient preference and adherence
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.885
H-Index - 48
ISSN - 1177-889X
DOI - 10.2147/ppa.s289139
Subject(s) - medicine , discontinuation , chronic lymphocytic leukemia , adverse effect , oncology , intensive care medicine , leukemia
Treatment for chronic lymphocytic leukemia (CLL) has changed dramatically with the approval of novel agents. Information regarding how patients and oncologists make trade-offs across attributes of novel therapies is limited. The purpose of this study was to understand how variations in attributes impact treatment choice among patients and oncologists.